Keros Therapeutics, Inc.
KROS
Price:
$56.98
Market Cap:
$2.14B
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, whi...[Read more]
Industry
Biotechnology
IPO Date
2020-04-08
Stock Exchange
NASDAQ
Ticker
KROS
The ROE as of September 2024 (TTM) for Keros Therapeutics, Inc. (KROS) is -44.73%
According to Keros Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -44.73%. This represents a change of 291.53% compared to the average of -11.42% of the last 4 quarters.
Keros Therapeutics, Inc. (KROS) Historical ROE (quarterly & annually)
How has KROS ROE performed in the past?
The mean historical ROE of Keros Therapeutics, Inc. over the last ten years is -60.37%. The current -44.73% ROE has changed -25.91% with respect to the historical average. Over the past ten years (40 quarters), KROS's ROE was at its highest in in the June 2019 quarter at 0%. The ROE was at its lowest in in the December 2019 quarter at -50.47%.
Average
-60.37%
Median
-30.95%
Minimum
-226.45%
Maximum
-10.46%
Keros Therapeutics, Inc. (KROS) ROE by Quarter and Year
Discovering the peaks and valleys of Keros Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 2.06%
Maximum Annual ROE = -10.46%
Minimum Annual Increase = -92.35%
Minimum Annual ROE = -226.45%
| Year | ROE | Change |
|---|---|---|
| 2023 | -46.05% | 22.05% |
| 2022 | -37.73% | 56.20% |
| 2021 | -24.16% | 39.38% |
| 2020 | -17.33% | -92.35% |
| 2019 | -226.45% | 2.06% |
Keros Therapeutics, Inc. (KROS) Average ROE
How has KROS ROE performed in the past?
The current ROE of Keros Therapeutics, Inc. (KROS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-35.98%
5-year avg
-70.35%
10-year avg
-60.37%
Keros Therapeutics, Inc. (KROS) ROE vs. Peers
How is KROS’s ROE compared to its peers?
Keros Therapeutics, Inc.’s ROE is greater than IDEAYA Biosciences, Inc. (-20.53%), greater than AnaptysBio, Inc. (-255.67%), greater than MeiraGTx Holdings plc (-86.28%), greater than Homology Medicines, Inc. (-100.91%), greater than Janux Therapeutics, Inc. (-8.78%), greater than Fennec Pharmaceuticals Inc. (-52.10%), greater than Edgewise Therapeutics, Inc. (-28.01%), less than Harmony Biosciences Holdings, Inc. (22.97%), greater than Aerovate Therapeutics, Inc. (-83.65%), greater than Syndax Pharmaceuticals, Inc. (-57.42%), greater than Mineralys Therapeutics, Inc. (-42.61%), greater than Replimune Group, Inc. (-52.15%), greater than Erasca, Inc. (-131.94%), greater than Century Therapeutics, Inc. (-65.37%), greater than NGM Biopharmaceuticals, Inc. (-76.46%), greater than Monte Rosa Therapeutics, Inc. (-70.40%), greater than Surrozen, Inc. (-178.66%), greater than Bolt Biotherapeutics, Inc. (-61.40%), greater than Larimar Therapeutics, Inc. (-37.84%), greater than Kezar Life Sciences, Inc. (-54.50%),
| Company | ROE | Market cap |
|---|---|---|
| -20.53% | $3.16B | |
| -255.67% | $1.22B | |
| -86.28% | $328.95M | |
| -100.91% | $3.02M | |
| -8.78% | $2.61B | |
| -52.10% | $149.68M | |
| -28.01% | $1.77B | |
| 22.97% | $2.21B | |
| -83.65% | $54.85M | |
| -57.42% | $1.63B | |
| -42.61% | $584.79M | |
| -52.15% | $760.42M | |
| -131.94% | $839.04M | |
| -65.37% | $135.55M | |
| -76.46% | $128.53M | |
| -70.40% | $373.15M | |
| -178.66% | $27.51M | |
| -61.40% | $23.29M | |
| -37.84% | $459.41M | |
| -54.50% | $41.59M |
Build a custom stock screener for Keros Therapeutics, Inc. (KROS) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Keros Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Keros Therapeutics, Inc. (KROS) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Keros Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Keros Therapeutics, Inc.'s ROE?
How is the ROE calculated for Keros Therapeutics, Inc. (KROS)?
What is the highest ROE for Keros Therapeutics, Inc. (KROS)?
What is the 3-year average ROE for Keros Therapeutics, Inc. (KROS)?
What is the 5-year average ROE for Keros Therapeutics, Inc. (KROS)?
How does the current ROE for Keros Therapeutics, Inc. (KROS) compare to its historical average?